CN102872010B - Application of Aphanamixoid A in drugs for treating ovarian cancer - Google Patents
Application of Aphanamixoid A in drugs for treating ovarian cancer Download PDFInfo
- Publication number
- CN102872010B CN102872010B CN201210414051.XA CN201210414051A CN102872010B CN 102872010 B CN102872010 B CN 102872010B CN 201210414051 A CN201210414051 A CN 201210414051A CN 102872010 B CN102872010 B CN 102872010B
- Authority
- CN
- China
- Prior art keywords
- aphanamixoid
- ovarian cancer
- drugs
- application
- preparing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229930193702 aphanamixoid Natural products 0.000 title claims abstract description 25
- 206010033128 Ovarian cancer Diseases 0.000 title claims abstract description 19
- 206010061535 Ovarian neoplasm Diseases 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 17
- 229940079593 drug Drugs 0.000 title abstract description 9
- 238000002360 preparation method Methods 0.000 claims description 8
- 230000012010 growth Effects 0.000 abstract description 7
- 108700024827 HOC1 Proteins 0.000 abstract description 6
- 101100178273 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) HOC1 gene Proteins 0.000 abstract description 6
- 230000002401 inhibitory effect Effects 0.000 abstract description 5
- 230000000694 effects Effects 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 2
- 238000011156 evaluation Methods 0.000 abstract description 2
- OAVCWZUKQIEFGG-UHFFFAOYSA-O 2-(5-methyl-2H-tetrazol-1-ium-1-yl)-1,3-thiazole Chemical compound CC1=NN=N[NH+]1C1=NC=CS1 OAVCWZUKQIEFGG-UHFFFAOYSA-O 0.000 abstract 1
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 description 9
- 240000003906 Aphanamixis grandifolia Species 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000002246 antineoplastic agent Substances 0.000 description 3
- 229940041181 antineoplastic drug Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 150000002630 limonoids Chemical class 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- JOKGCLXRONOYBU-UHFFFAOYSA-N C#CC1=CCCC2C1=CCC2 Chemical compound C#CC1=CCCC2C1=CCC2 JOKGCLXRONOYBU-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241001597008 Nomeidae Species 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000001887 anti-feedant effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000012531 culture fluid Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000206 health hazard Toxicity 0.000 description 1
- 150000002611 lead compounds Chemical class 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses an application of Aphanamixoid A in preparing drugs for treating ovarian cancer and belongs to the technical field of new uses of the drugs. Discovered by extracorporeal methyl thiazolyl tetrazolium (MTT) antineoplastic activity evaluation, the Aphanamixoid A disclosed by the invention is also remarkable in action of inhibiting the growth of human ovarian cancer cell strains HO-8910, HOC1 and OVAC. Therefore, the Aphanamixoid A can be used for preparing the drugs for resisting the ovarian cancer, and is good in development and application prospect. The application of the Aphanamixoid A in preparing the drugs for treating the ovarian cancer is disclosed for the first time. The skeleton type of the Aphanamixoid A is fire-new, and moreover, how high the activity of inhibiting human ovarian cancer cells is unexpected.
Description
Technical field
The present invention relates to the new purposes of compd A phanamixoid A, relate in particular to the application of Aphanamixoid A in preparing ovarian cancer resistance medicament.
Technical background
Cancer is to one of disease of human life's health hazard maximum, has a large amount of people to die from cancer every year.The research and development of cancer therapy drug are the focuses of study of pharmacy always.In antitumor drug, have 74% to be natural product or derivatives thereof, if paclitaxel and derivant thereof are exactly the reasonable antitumor drug of effect clinically at present.Therefore, from natural product, find anticancer compound or lead compound has great importance.
The compd A phanamixoid A the present invention relates to is one and within 2012, delivers (Cai, J. Y. et al., 2012. Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.) New skeleton compound, this compound has brand-new framework types, current purposes only relates to insect antifeedant activity (Cai, J. Y. et al., 2012. Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.), purposes for the Aphanamixoid A the present invention relates in preparation treatment ovarian cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for ovarian cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possesses outstanding substantive distinguishing features, control for ovarian cancer simultaneously obviously has significant progress.
Summary of the invention
The invention provides the application of compd A phanamixoid A in preparing antitumor drug.
The present invention adopts following technical scheme: the application of Aphanamixoid A in preparing ovarian cancer resistance medicament, and the structural formula of Aphanamixoid A is as shown in formula I:
The present invention finds by the evaluation of external MTT anti-tumor activity, and Aphanamixoid A also has significant inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC, suppresses the IC of this 3 strain Growth of Cells
50value is respectively 0.25 ± 0.07 μ M, 0.33 ± 0.07 μ M and 0.11 ± 0.06 μ M.Therefore, Aphanamixoid A can, for the preparation of ovarian cancer resistance medicament, have good development prospect.
The purposes of the Aphanamixoid A the present invention relates in preparation treatment ovarian cancer medicine belongs to open first, because framework types belongs to brand-new framework types, and its inhibition for ovarian cancer cell is active unexpectedly strong, there is not the possibility that is provided any enlightenment by other compounds, possess outstanding substantive distinguishing features, the control for ovarian cancer simultaneously obviously has significant progress.
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
The specific embodiment
The preparation method of compd A phanamixoid A involved in the present invention is referring to document (Cai, J. Y. et al., 2012. Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya. Organic Letters 14 (10), 2524 – 2527.).
The present invention is further detailed explanation by the following examples, but protection scope of the present invention is not subject to any restriction of specific embodiment, but be limited by claim.
Embodiment 1: the preparation of compd A phanamixoid A tablet involved in the present invention:
Get 20 and digest compound Aphanamixoid A, add 180 grams of conventional adjuvants preparing tablet, mix, conventional tablet machine is made 1000.
Embodiment 2: the preparation of compd A phanamixoid A capsule involved in the present invention:
Get 20 and digest compound Aphanamixoid A, add the conventional adjuvant of preparing capsule as 180 grams of starch, mix, encapsulatedly make 1000.
Below by pharmacodynamic experiment, further illustrate its pharmaceutically active.
Experimental example: adopt the growth inhibited effect of mtt assay assessing compound Aphanamixoid A to human oophoroma cell line
1. method: the cell in growth logarithmic (log) phase: human oophoroma cell line HO-8910, HOC1 and OVAC(buy from Chinese Academy of Sciences's cell bank) with 1.5 * 10
4concentration kind is in 96 orifice plates.After cell culture 24 h are adherent, suck original culture medium.Test is divided into blank group, drug treating group.Blank group is changed 1640 culture medium containing 10% hyclone; It is 100 μ M that drug treating group is changed containing concentration, 50 μ M, 10 μ M, 1 μ M, 0.1 μ M, the culture medium of the Aphanamixoid A of 0.01 μ M and 0.001 μ M.Cultivate after 48 h, add the MTT of concentration 5mg/mL, continue to be put in CO
2incubator is cultivated 4 h, then along culture fluid top, suck 100 μ L supernatants, add 100 μ L DMSO, 10 min are placed in dark place, utilize microplate reader (Sunrise company product) to measure light absorption value (wavelength 570nm), and calculating cell survival situation according to light absorption value, 6 repeating holes are established in each processing.Cell survival rate (%)=Δ OD
drug treating/ Δ OD
blank* 100.
2. result: Aphanamixoid A has significant inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC.This compound suppresses the IC of human oophoroma cell line HO-8910, HOC1 and OVAC growth
50value is respectively: 0.25 ± 0.07 μ M, 0.33 ± 0.07 μ M and 0.11 ± 0.06 μ M.
By above-described embodiment, shown, Aphanamixoid A of the present invention has good inhibitory action to the growth of human oophoroma cell line HO-8910, HOC1 and OVAC.Prove thus, Aphanamixoid A of the present invention has ovarian cancer resistance activity, can be for the preparation of ovarian cancer resistance medicament.
Claims (1)
- The application of 1.Aphanamixoid A in preparation treatment ovarian cancer medicine, described compd A phanamixoid A structure is as shown in formula I:
Formula I.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210414051.XA CN102872010B (en) | 2012-10-25 | 2012-10-25 | Application of Aphanamixoid A in drugs for treating ovarian cancer |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210414051.XA CN102872010B (en) | 2012-10-25 | 2012-10-25 | Application of Aphanamixoid A in drugs for treating ovarian cancer |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102872010A CN102872010A (en) | 2013-01-16 |
| CN102872010B true CN102872010B (en) | 2014-04-16 |
Family
ID=47473684
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210414051.XA Active CN102872010B (en) | 2012-10-25 | 2012-10-25 | Application of Aphanamixoid A in drugs for treating ovarian cancer |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102872010B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1580043A (en) * | 2003-08-04 | 2005-02-16 | 财团法人佛教慈济综合医院 | Anti malignant tumour southern radix bupleuri extract preparing method |
| CN101978959A (en) * | 2010-10-18 | 2011-02-23 | 天津尚德药缘科技有限公司 | Application of sphaelactone and derivative thereof to treatment of cancers |
-
2012
- 2012-10-25 CN CN201210414051.XA patent/CN102872010B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1580043A (en) * | 2003-08-04 | 2005-02-16 | 财团法人佛教慈济综合医院 | Anti malignant tumour southern radix bupleuri extract preparing method |
| CN101978959A (en) * | 2010-10-18 | 2011-02-23 | 天津尚德药缘科技有限公司 | Application of sphaelactone and derivative thereof to treatment of cancers |
Non-Patent Citations (2)
| Title |
|---|
| Aphanamixoid A, a Potent Defensive Limonoid, with a New Carbon Skeleton from Aphanamixis polystachya;Jie-Yun Cai, et al.;《ORGANIC LETTERS》;20120427;第14卷(第10期);2524–2527 * |
| Jie-YunCai et al..Aphanamixoid A |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102872010A (en) | 2013-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102885809B (en) | Application of Aphanamixoid A in preparing medicament for treating pancreatic cancer | |
| CN102872010B (en) | Application of Aphanamixoid A in drugs for treating ovarian cancer | |
| CN102885806B (en) | Application of Aphanamixoid A in preparation of drug for treating laryngeal cancers | |
| CN102872073B (en) | Application of Houttuynoid C in preparing drugs for treating ovarian cancer | |
| CN102872080B (en) | Application of Houttuynoid A in drugs for treating cervical cancer | |
| CN103120678A (en) | Application of Aphanamixoid A in medicine for treating liver cancer | |
| CN102872142B (en) | Application of Houttuynoid D in drug for treating ovarian cancer | |
| CN102895224A (en) | Application of Aphanamixoid A in drugs for treating breast cancer | |
| CN103127091A (en) | Application of Aphanamixoid A in medicines curing colorectal cancer | |
| CN102872137B (en) | Application of Houttuynoid B in drug for treating cervical cancer | |
| CN102872085B (en) | Application of Houttuynoid A in medicines for treating breast cancer | |
| CN102872125B (en) | Application of Houttuynoid C in medicament for treating cervical cancer | |
| CN102861096B (en) | Application of Houttuynoid E in preparing medicine for treating cervical cancer | |
| CN102861077B (en) | Application of Houttuynoid D in medicine for treating cervical cancer | |
| CN102885843B (en) | Application of Houttuynoid B in medicament for treating breast cancer | |
| CN103120666A (en) | Application of Aphanamixoid A in medicine for treating human cervical carcinoma | |
| CN103120680A (en) | Application of Aphanamixoid A in medicine for treating nasopharyngeal carcinoma | |
| CN103120682A (en) | Application of Aphanamixoid A in medicine for treating bladder cancer | |
| CN103120679A (en) | Application of Aphanamixoid A in medicine for treating tongue cancer | |
| CN103356545A (en) | Application of Sarcaboside B in medicine used for treating ovarian cancer | |
| CN103127080A (en) | Application of Aphanamixoid A in medicines curing skin cancer | |
| CN103479632A (en) | Application of Lycojaponicumin B in preparation of drugs for treating cervical carcinoma | |
| CN103127090A (en) | Application of Aphanamixoid A in medicines curing kidney cancer | |
| CN103432141A (en) | Application of Chukrasone A in preparation of medicaments for treating ovarian cancer | |
| CN103462958A (en) | Application of Incarviatone A in medicaments for treating tongue cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: RUDONG TECHNOLOGY CENTER Free format text: FORMER OWNER: NANJING UNIVERSITY Effective date: 20141229 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210093 NANJING, JIANGSU PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20141229 Address after: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee after: Rudong science and Technology Center Address before: 210093 Nanjing, Gulou District, Jiangsu, No. 22 Hankou Road Patentee before: Nanjing University |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20200423 Address after: No. 10, Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee after: Rudong industrial and commercial information consulting service center Address before: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee before: Rudong science and Technology Center |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20211222 Address after: Fengli town Xinjian West Road, Rudong County, Nantong City, Jiangsu Province 226400 Patentee after: Rudong Wenyuan investment and Development Co., Ltd Address before: 226400 No.10 Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee before: Rudong industrial and commercial information consulting service center |
|
| TR01 | Transfer of patent right |